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Abstract 
BACKGROUND: In recent years, the prevalence of poisoning has increased dramatically due to population 
growth and access to drugs and toxins. Today poisoning is one of the important reasons for visiting hospitals.  
AIM: The present study aimed to investigate the effect of magnesium sulfate on organophosphorous toxicity. 
METHODS: Patients who had inclusion criteria in the study were randomly assigned to one of two groups (control 
group or case group) by an emergency medicine specialist. Patients' data including age, sex, ECG, vital signs, 
arterial oxygen saturation were recorded for patients. Patients in the case group (40 subjects) received 2 mg 
magnesium sulfate 50%, while the control group (40 subjects) received 100 cc normal saline (as placebo) as an 
intravenous infusion 
RESULTS: The distribution of gender in the two groups of patients was the same. Also, the mean age, Stature 
and weight of patients were similar in both groups. In the group receiving magnesium sulfate, diastolic blood 
pressure was lower when compared with another group, at 0 and 2 hours after intervention. Moreover, the mean 
of systolic blood pressure in both groups was determined to be the same at all hours. Furthermore, the heart rate 
in the group receiving sulfate was lower as compared to the control group for 8 hours, 16 and 24 hours after 
intervention.  
CONCLUSION: The use of magnesium sulfate in organophosphate poisoning reduces therapeutic costs an 
average hospital length of stay and mortality compared to those who did not receive magnesium sulfate. 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
In recent years, the prevalence of poisoning 
has increased dramatically due to the growth of 
societies and the ease of access to drugs and toxins 
[1]. In Iran, over 50 various pesticide combinations are 
utilised for agriculture, and today in Iran there are over 
40 organophosphorus chemicals (OPs), with acute 
and subacute toxicity, as well as OPs, are applied in 
agronomy, homes, gardens and veterinary practice. 
[2]. Usually, the severity of poisoning in adolescents 
and adults is often acute, due to excessive 
consumption of oral medications or the misuse of 
some medications, environmental, industrial, and 
available agricultural products deliberately or 
accidentally [3] [4]. 
In general, the incidence of poisoning is quite 
different in each region and each country due to the 
geographical distribution of each particular region and 
the type of toxic substance [5] [6]. Many of the 
poisonings are drug-related, and the rest are 
classified as non-drug poisoning. Generally, common 
causes of poisoning include drugs, hydrocarbons, 
organophosphorus pesticides (OPPs), natural 
anticholinergic or chemical compounds, rodenticide, 
opiate, carbon monoxide, alcohol, fungi, insect and 
animal bites, acid and basic materials [5] [7]. 
Pesticides, especially organophosphorus, are 
distributed in many areas, to fight pest infestations. 
Because of their ease of access, poisoning from them 
has become more prevalent. Organophosphate 
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poisoning is one of the main clinical problems in the 
world, especially in developing countries, where is 
associated with high mortality [5] [8] [9]. About 28.4% 
of the agricultural pesticides used in Iran are 
organophosphorus [10]. Insecticides are 
organophosphorus compounds that lead to toxicity in 
humans by inhibiting the acetylcholinesterase enzyme 
[11]. As other studies indicated, the mortality rate from 
organophosphate poisoning has been reported by 3 to 
25% [12]. The most common cause of death in this 
poisoning is respiratory failure due to respiratory 
depression, resulting from respiratory muscle 
weakness, central nervous system suppression, 
bronchus, bronchospasm and bradycardia [13]. 
Although poisoning and contamination with this toxin 
occur in all countries, in third world countries due to 
the low level of industrial and health care, the annual 
incidence of organophosphate poisoning and mortality 
is higher [14]. In Iran, organophosphate is widely used 
as an insecticide poison in the agricultural industry. 
According to a study conducted in Isfahan, this 
substance was the fourth most common poisoning 
and the second leading cause of death in patients 
referring to the poisoning department of the Noor 
Medical Center [15]. Magnesium sulfate is an 
inorganic salt containing magnesium, sulfur and 
oxygen, with the formula MgSO4. The mechanism of 
magnesium effect is not well known but affects the Na 
+ K + ATPase pump in sodium, potassium and 
calcium channels. It also reduces the release of 
acetylcholine at the site of the nerve-muscle. 
The drug is used for various purposes, such 
as eliminating magnesium deficiency, helping to treat 
lethal arrhythmias called torsade, and preventing 
eclamptic seizure, as well as treating severe asthma 
and preventing premature uterine contractions during 
pregnancy. This drug prevents seizures or control of 
these attacks by blocking neuromuscular transmission 
[16]. Poisoning with this drug is not common, but 
excessive use of this drug can cause flushing and 
sweating, low blood pressure and reduced tendon 
reflexes. Atropine and oximes are traditionally used in 
the management of poisoning, but their efficacy is a 
subject of debate [17] [18] [19] [20] [21]. Animal 
findings indicate the low efficacy of pralidoxime in 
organophosphate poisoning [22] [23]. On the other 
hand, evidence suggests that it does not affect human 
poisoning [17] [19] [24]. 
Therefore, any pharmacotherapeutic agent 
that contributes to preventing or improving the toxicity 
of OPPs can also be helpful in reducing the cost of 
treatment and the length of hospitalisation. Animal 
experiments and uncontrolled human experiments 
demonstrate the effect of MgSO4 [25] and clonidine for 
reducing organophosphate toxicity. Given the 
evidence mentioned above, the present study was 
conducted to investigate the effect of magnesium 
sulfate on organophosphate toxicity. 
 
Material and Methods 
 
Ethical approval and patient consents 
All procedures performed in studies involving 
human participants were by the ethical standards of 
the institutional and/or national research committee 
and with the 1964 Helsinki Declaration and its later 
amendments or comparable ethical standards. The 
study protocol was approved by the Ethics Committee 
of Arak University of Medical Sciences. Patients who 
contacted us indicated their consent by signing a 
written consent form. 
 
Study design and patient populations 
This double-blind, randomised clinical trial 
was conducted on patients referred to the emergency 
department of Vali-e-Asr Hospital in Arak, Iran with 
symptoms of organophosphate poisoning. The 
diagnosis of this poisoning is based on a history of 
contact with these agents and specific clinical signs of 
poisoning, which are presented as follows: 
Defecation/Diarrhea, Urination, Muscle Weakness/ 
Miosis, Bradycardia/ Bronchorrhea/ Bronchospasm, 
Emesis, Tears Lacrimation, Salivation, which is called 
DUMBLE. 
Patients in the case group (40 patients) 
received 2 g of magnesium sulfate 50% (4 cc) for 
intravenous infusion in a total volume of 100 cc, in half 
an hour.  The same amount of drug (2 g) was 
successively injected 3 times every 2 hours. The drug 
was prepared by a nurse and under the supervision of 
a specialist in emergency medicine and was provided 
to the corresponding person who was not aware of the 
type of medication.  
In the control group, 100 cc normal saline (as 
placebo) injected intravenously in half an hour for 
patients in the control group (40 patients). The same 
amount of drug (100 cc normal saline) was 
successively injected 3 times for half an hour. It 
should be noted that all patients in each of the two 
groups received the standard medicine, suggested in 
the reference books for organophosphate poisoning. 
Standard treatment consists of gastric lavage, 
serum administration, oxygen intake, pulmonary and 
oral secretions suction, cardiopulmonary and 
respiratory monitoring, charcoal administration (1 
g/kg), and washing of infected skin with water and 
soap, and intravenous injection of 0.5-5 mg atropine. 
The dosage of Pralidoxime is 20-40 mg/kg, which is 
administered intravenously throughout 10 to 5 
minutes. Pralidoxime can be repeated every 6 to 24 
hours, if necessary. 
Keeping the airway open, oxygen was given 
and fixation of hypertension during treatment. Other 
factors were also evaluated, including electrolytes, 
fasting blood sugar, liver and kidney function tests, 
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arterial blood gases, pupil size, tendon reflexes, 
fasciculations intensity, respiratory crackles and oral 
secretions, and in the case of tracheal intubation. 
Also, if intubation was done, the secretion of the chip 
was checked, and the levels of atropine and 
pralidoxime were also recorded. 
All data were analysed by SPSS software 
v.19. The variables were applied to measure the 
mean, standard deviation, standard error, percentage 
of frequency. Covariance analysis, Chi-square and 
Independent T-test or its nonparametric equation were 
also used to compare the variables. 
The inclusion criteria included: 1. Age 
between 18-65 years; 2. Patients with acute OPPs 
toxicity who have not received advanced medical care 
at the other medical centre and less than two hours 
after the time of their poisoning; 3. Filling out the 
informed consent form of the patient. 
Exclusionary criteria include 1. Unwilling to 
participate in the study; 2. The concomitant use of 
other drugs as a coincidence or suicide attempt; 3. 
History of severe complications or sensitisation due to 
magnesium sulfate; 4. History of the known cardiac 
block, cardiovascular injury, myocardial injury due to 
previous MI, severe renal failure, hepatitis, Addison's 
disease.  
The sample size was calculated based on α = 
0.05, and generalising the prevalence to a country 
(0.062), [26]. Finally, 40 subjects were assigned to 
each group, where the total sample size was 
estimated as 80 based on the formula below. 
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All data were analysed by SPSS software 
v.19. The variables were applied to measure the 
mean, standard deviation, standard error, percentage 
of frequency. Covariance analysis, Chi-square and 
Independent T-test or its nonparametric equation were 
also used to compare the variables. 
 
 
Results 
 
This double-blind, randomised clinical trial 
was conducted on patients with organophosphate 
poisoning symptoms. Therefore, 90 patients were 
enrolled in the study and 10 were excluded from the 
study, of which 3 patients died before 24 hours, and 3 
subjects used carbamate insecticide that was 
discharged from the hospital after 18 hours of 
admission and a relative improvement. Furthermore, 
one case of advanced liver cancer was excluded. 
With regard to gender, the case group 
consisted of 25 (62.5%) males and 15 (37.5%) 
women, while the control group consisted of 22 (55%) 
males and 18 (45%), there was no statistically 
significant difference between two groups in terms of 
gender and both groups were poisoned in the same 
ratio (P = 0.391). 
The mean and standard deviation of age in 
control and case groups were determined to be 35.90 
± 10.53 and 29.90 ± 8.87 years, respectively, where 
there was no statistically significant difference 
between the two groups regarding age and both 
groups were matched regarding mean age (P = 
0.059). 
The mean and standard deviation of weight in 
groups with or without sulfate were estimated as 71.4 
± 11.43 kg and 72.90 ± 11.19 kg, respectively. There 
was no statistically significant difference between the 
two groups regarding weight (P = 0.677). 
Furthermore, mean and standard deviation of 
stature in groups with or without sulfate were 
determined to be166.30 ± 11.07 and 168.60 ± 11.05 
cm, respectively, no significant difference was found 
regarding stature in the two groups (P = 0.515). 
The mean systolic blood pressure in both 
groups between 0 to 24 hours after the intervention 
was not statistically significant (Table 1). 
Table 1: Mean systolic blood pressure in both groups 
 Group Mean 
Standard 
Deviation  
P value 
SBP 
Zero hour 
Without sulfate 531 51.53 
551.0 
With sulfate 533 00.50 
SBP 
2 hours later 
Without sulfate 525 56.5 
505.0 
With sulfate 10/530 15.53 
SBP 
4 hours later 
Without sulfate 525 56.5 
516.0 
With sulfate 10/530 51.55 
SBP 
6 hours later 
Without sulfate 30/525 56.5 
160.0 
With sulfate 21/535 50.55 
SBP 
8 hours later 
Without sulfate 533 23.5 
001.0 
With sulfate 10/533 21.52 
SBP 
16 hours later 
Without sulfate 01/530 56.5 
255.0 
With sulfate 51/533 32.52 
SBP 
24 hours later 
Without sulfate 532 15.5 
025.0 
With sulfate 11/535 00.52 
 
The mean and standard deviation of diastolic 
blood pressure 0 and 2 hours after intervention in the 
two groups showed a statistically significant 
difference, indicating that the magnesium sulfate 
group had higher blood pressure in these time zones 
than the group without magnesium sulfate (P = 0.004; 
P = 0.004). However, our results didn’t show (Table 2) 
significant statistical difference for the remaining hours 
(Table 2). 
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Table 2: Mean diastolic blood pressure in both groups 
 Group Mean 
Standard 
Deviation 
P value 
DBP 
Zero hour 
Without sulfate 61.65 66.6 
005.0 
With sulfate 50.62 30.5 
DBP 
2 hours later 
Without sulfate 51.66 50.6 
005.0 
With sulfate 51.65 05.1 
DBP 
4 hours later 
Without sulfate 30.66 15.6 
655.0 
With sulfate 50.65 35.6 
DBP 
6 hours later 
Without sulfate 30.66 10.6 
555.0 
With sulfate 11.61 60.5 
DBP 
8 hours later 
Without sulfate 00.61 05.5 
553.0 
With sulfate 50.66 00.5 
DBP 
16 hours later 
Without sulfate 50.65 05.6 
000.5 
With sulfate 50.61 05.6 
DBP 
24 hours later 
Without sulfate 50.65 02.6 
325.0 
With sulfate 50.65 55.6 
 
As indicated in Table 3, the mean and 
standard deviation of heart rate 8, 16, and 24 hours 
after intervention in the two groups showed a 
statistically significant difference, indicating that at 
these times, patients receiving magnesium sulfate had 
a lower heart rate per minutes (P = 0.028; P = 0.001; 
P = 0.017). 
Table 3: Average heart rate (Pr) in both groups 
Group  Mean 
Standard 
Deviation 
P value 
Pr 
Zero hour 
Without sulfate 50.16 36.1 
535.0 
With sulfate 60.11 51.3 
Pr 
2 hours later 
Without sulfate 51.506 36.55 
616.0 
With sulfate 20.500 55.5 
Pr 
4 hours later 
Without sulfate 01.501 00.50 
212.0 
With sulfate 11.505 50.50 
Pr 
6 hours later 
Without sulfate 50.505 32.50 
500.0 
With sulfate 10.505 25.5 
Pr 
8 hours later 
Without sulfate 11.505 53.5 
020.0 
With sulfate 50.50 61.1 
Pr 
16 hours later 
Without sulfate 00.505 26.5 
005.0 
With sulfate 21.52 55.3 
Pr 
24 hours later 
Without sulfate 20.51 26.5 
056/0 
With sulfate 01.50 56.5 
 
There was no significant difference between 
the two groups in the number of breaths per minute at 
0, 2, 4, 6, 8, 16, 24 hours after intervention. Moreover, 
No significant difference was found in the mean of 
arterial oxygen in the two groups at 0, 2, 4, 6, 8, 16, 
24 hours after intervention. 
Distribution of intubation frequency at 0, 2, 4, 
6, 8, 16, 24 hours after intervention showed no 
statistically significant difference between the two 
groups regarding the need for intubation (Figure 1). 
 
Figure 1: Frequency distribution of patients who were intubated at 
0, 2, 4, 6, 8, 16, and 24 hours, based on the group 
The frequency of pulmonary secretions at 0, 
2, 4, 6, 8, 16, 24 hours after the intervention was not 
significantly different between the two groups and the 
lung secretions in both groups were approximately 
equal to one. 
Moreover, the mean and standard deviation of 
admission hours showed that the use of magnesium 
sulfate in organophosphate poisoning reduced the 
number of admission hours (P = 0.006), (Table 4). 
Table 4: Average hospitalization hours in both groups 
Group Mean 
Standard 
Deviation 
P value 
Hospitali-
zation  
Without sulfate 01.10 56.52 005.0 
 
Furthermore, the mean and standard 
deviation of atropine did not show a significant 
difference in the mean of atropine consumption (P = 
67.9), (Table 5).  
Table 5: Average atropine consumed in patients in both groups 
Group Mean(mg) 
Standard 
Deviation 
P value 
atropine 
Without sulfate 5060 50 
565.0 
With sulfate 5000 51 
 
Additionally, the mean and standard deviation 
of consumed Pralidoxime exhibited no significant 
difference (P = 0.232), (Table 6).  
Table 6: The mean of consumed Pralidoxime at the end of 24 
hours in patients in both groups 
Group Mean(g) 
Standard 
Deviation 
P value 
Pralidoxime 
Without sulfate 355 25 
232.0 
With sulfate 312 22 
 
On the other hand, the distribution of pupil 
diameter in both groups at 0, 2, 4, 6, 8, 16, 24 hours 
after intervention suggested no statistically significant 
difference (Table 7). 
Table 7: Distribution of pupil diameter in both groups 
Pupil diameter 
Group 
P value Without 
sulfate 
With sulfate 
Zero hour 
Lower 3 mm 20 20 
- Between 3 and 6 mm 0 0 
Up to 6 mm 0 0 
2 hours later 
Lower 3 mm 2 5 
025.0 Between 3 and 6 mm 50 5 
Up to 6 mm 5 5 
4 hours later 
Lower 3 mm 0 0 
000.5 Between 3 and 6 mm 5 3 
Up to 6 mm 55 56 
6 hours later 
Lower 3 mm 0 0 
000.5 Between 3 and 6 mm 5 3 
Up to 6 mm 55 56 
8 hours later 
Lower 3 mm 0 0 
305.0 Between 3 and 6 mm 5 0 
Up to 6 mm 55 52 
16 hours later 
Lower 3 mm 0 0 
650.0 Between 3 and 6 mm 53 55 
Up to 6 mm 6 5 
4 hours later 
Lower 3 mm 0 0 
105.0 Between 3 and 6 mm 51 52 
Up to 6 mm 1 0 
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Discussion 
 
This study aimed to investigate the effect of 
magnesium sulfate on organophosphate poisoning. 
Organophosphate poisoning is one of the main clinical 
problems in the world with thousands of victims per 
year [27]. By inhibiting acetylcholinesterase activity, 
these compounds cause acetylcholine to accumulate 
in some brain synapses and neuromuscular 
synapses. Organophosphate poisoning is defined by 
various disorders such as the four clinical syndromes, 
cholinergic crisis, interstitial syndrome, 
organophosphate-induced delayed polyneuropathy 
(OPIDP), and organophosphate-induced chronic 
neuromuscular disorders. Each of these syndromes 
has its symptoms and symptoms [28]. Patients who 
receive first auxiliary treatment and emergency 
medical treatment have a better chance of recovery. 
However, the presence of arrhythmia and respiratory 
failure associated with poor prognosis. Ultimately, 
early diagnosis and proper treatment of complications 
can potentially reduce mortality. 
Based on results presented in this study, the 
frequency of gender distribution was similar in both 
groups of patients and also the mean age, stature and 
weight of patients in both groups were determined to 
be similar. In the group receiving magnesium sulfate, 
diastolic blood pressure was found to be lower 0 and 
2 hours after intervention as competed to patients who 
did not receive sulfate. The mean of systolic blood 
pressure in both groups was the same at all hours. 
The heart rate per minute in 8, 16 and 24 hours after 
the intervention was lower in the magnesium sulfate 
group than patients without receiving magnesium 
sulfate. Also, the number of hospital days in the group 
receiving magnesium sulfate was lower than that of 
other patients. 
MgSO4 inhibits acetylcholine release in the 
central nervous system, peripheral sympathetic and 
parasympathetic synapses. This prevents calcium 
channels in presynaptic nerve terminals, which 
release acetylcholine and increases the hydrolysis of 
some pesticides. It reduces arrhythmias associated 
with organophosphorus compounds and atropine, in 
the central nervous system decreases overstimulation 
by organophosphorus compounds, acting on the N-
methyl-D-aspartate receptor, and reverses 
neuromuscular faint in the peripheral nervous system 
[29] [30] [31]. 
In the study of Pajoumand et al., The use of 
MgSO4 at a dose of 4 g/day was considered useful in 
the treatment of acute human organophosphate 
toxicity, leading to a decrease in hospitalisation days 
and mortality rates that were consistent with the 
results of our study [32]. Our study also revealed that 
the number of hospital days in patients receiving 
magnesium sulfate was higher than those who did not 
receive magnesium sulfate, where reduces the cost of 
treatment. Basher in 2013 investigated the effect of 
magnesium sulfate on the toxicity of acute 
organophosphorus pesticides, and no adverse effects 
of magnesium were reported. In our study, no adverse 
effects were also found in patients receiving 
magnesium sulfate [33]. 
Recent advances in the treatment of 
organophosphate pesticide poisoning have shown 
that the alkalization of blood with sodium bicarbonate 
and magnesium sulfate can be promising auxiliary 
treatment [34], furthermore, Ahmed et al., in 2010, 
investigated the role of fresh plasma and magnesium 
sulfate in the treatment of acute toxicity of 
arganophosphamide insecticides, and showed that 
the addition of magnesium sulfate and fresh plasma to 
conventional treatments in organophosphate 
poisoning reduced the rate of hospitalization and 
death, where the results of this study were consistent 
with our findings [32]. 
In conclusion, the results of our study showed 
that the use of magnesium sulfate in 
organophosphate poisoning reduces therapeutic costs 
and the number of hospitalisation days and mortality 
compared to those who did not receive magnesium 
sulfate. Also, magnesium sulfate is also used to 
control tachycardia, ventricular arrhythmias, muscle 
fasciculations, where is therefore preferred to 
traditional therapies. 
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